Direct Medical Costs of Home-Based Respiratory Support and Oxygen Therapy for Patients With Chronic Respiratory Failure
Author(s)
Sergey Avdeev, PhD1, Diana Nevzorova, PhD2, Maria Avxentyeva, PhD3, Egor Larin, MD2, Galia Nuralieva, PhD2, Vadim Tkachenko, MPH2, Kirill Krokhin, MPH1.
1First Moscow State Medical University (Sechenov Univerity), Moscow, Russian Federation, 2First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, 3Fund for the Development of Social Policy and HealthCare “Helios”, Moscow, Russian Federation.
1First Moscow State Medical University (Sechenov Univerity), Moscow, Russian Federation, 2First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, 3Fund for the Development of Social Policy and HealthCare “Helios”, Moscow, Russian Federation.
OBJECTIVES: Access to home-based respiratory support is limited in Russian healthcare system, while the demand is growing. Understanding the costs and budget impact of this method is necessary for its wider implementation. The aim of this study was to assess the costs of managing patients with chronic respiratory failure (CRF) requiring long-term oxygen therapy (LOT), non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV) at home.
METHODS: Data on resource utilization were collected in a prospective observational real-world practice study (2021-2022) from medical records and patients’ diaries. 98 patients (mean age 61 years, 56.9% men) suffering from CRF due to 17 different diseases were included into the study. They received either OT (n=47) or NILV (n=43) or IMV (n=8) at home for a median duration of 9 months. Type of respiratory support was prescribed by the physician at the screening visit. Average cost of respiratory equipment and consumables were calculated based of mean market prices, medical and technical visits costs were estimated based of healthcare provider-payment rates. Results of the research are reported in 2023 US dollars (currency rate USD 1= RUB 85.8).
RESULTS: The weighted monthly average costs per one patient suffering from CRF was the highest for IMV at home: USD 1,351.35 (95% CI: USD 1,402.96 - USD 1,278.75). NIV was nearly 3 times cheaper: USD 465.09 (95% CI: 516.74 - 413.44) per patient per month. LTOT was the less costly and amounted to USD 122.59 (95% CI: 129.70 - 115.49). The main costs fell for the equipment. 998 of visits to patients were made in total (90% planned and 10% urgent), their cost was similar in all three groups.
CONCLUSIONS: The cost study of home-based respiratory support provides the information necessary for the budget impact analysis and the calculation of provider-payment fee in the healthcare system.
METHODS: Data on resource utilization were collected in a prospective observational real-world practice study (2021-2022) from medical records and patients’ diaries. 98 patients (mean age 61 years, 56.9% men) suffering from CRF due to 17 different diseases were included into the study. They received either OT (n=47) or NILV (n=43) or IMV (n=8) at home for a median duration of 9 months. Type of respiratory support was prescribed by the physician at the screening visit. Average cost of respiratory equipment and consumables were calculated based of mean market prices, medical and technical visits costs were estimated based of healthcare provider-payment rates. Results of the research are reported in 2023 US dollars (currency rate USD 1= RUB 85.8).
RESULTS: The weighted monthly average costs per one patient suffering from CRF was the highest for IMV at home: USD 1,351.35 (95% CI: USD 1,402.96 - USD 1,278.75). NIV was nearly 3 times cheaper: USD 465.09 (95% CI: 516.74 - 413.44) per patient per month. LTOT was the less costly and amounted to USD 122.59 (95% CI: 129.70 - 115.49). The main costs fell for the equipment. 998 of visits to patients were made in total (90% planned and 10% urgent), their cost was similar in all three groups.
CONCLUSIONS: The cost study of home-based respiratory support provides the information necessary for the budget impact analysis and the calculation of provider-payment fee in the healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE333
Topic
Economic Evaluation, Medical Technologies, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Geriatrics, Neurological Disorders, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)